Report of a case successfully treated with chemo-radiation against local recurrence after gastric cancer surgery

Takahiro Igarashi, Yoshiro Saikawa, Koshi Kumagai, Rieko Nakamura, Tsunehiro Takahashi, Yuya Takeuchi, Yuukou Kitagawa

Research output: Contribution to journalArticle

Abstract

A 68-year-old male was diagnosed as type 2 gastric cancer in the upper part of the stomach, then diagnosed as cT2 (MP) N0M0H0P0, cStage I B. Total gastrectomy and splenectomy with D2 lymph node dissection were performed. Final diagnosis including pathology was pT1 (SM) N1M0H0P0, pStage IB, and with his informed consent, an anti-cancer drug, UFT, was given as postoperative adjuvant therapy. Four months after the surgery, a 35-mm sized tumor recurring around the distal region of pancreas was detected by abdominal computed tomography (ACT). Then, combination chemo-radiotherapy using S-1, cisplatin and radiation (50 Gy) was performed. One year after the initial surgery, ACT showed a complete response (CR) of the recurred tumor, while outpatient chemotherapy with S-1+CPT-11 and S-1+paclitaxel was continuously performed, because of elevated CEA. Two years after initial surgery, the CEA value was elevated to 28.4 ng/mL, and so S-1 +docetaxel was applied. The patient is still alive with no sign of lesion recurrence by CT 3 years after initial surgery. Outpatient chemotherapy helped the patient maintain good quality of life. In addition, initial therapy for the recurred tumor including radiation proved to be a powerful way to control local growth of gastric cancer, even if hematogenous/lymphatic spreading of gastric cancer cells might be difficult to suppress with such chemo-radiotherapy.

Original languageEnglish
Pages (from-to)1363-1366
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume36
Issue number8
Publication statusPublished - 2009 Aug

Fingerprint

Stomach Neoplasms
Radiation
Recurrence
irinotecan
docetaxel
Neoplasms
Outpatients
Radiotherapy
Tomography
Radiation Dosage
Drug Therapy
Splenectomy
Gastrectomy
Paclitaxel
Lymph Node Excision
Informed Consent
Cisplatin
Pancreas
Stomach
Quality of Life

Keywords

  • Chemoradiation therapy
  • Recurrent gastric cancer
  • S-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Report of a case successfully treated with chemo-radiation against local recurrence after gastric cancer surgery. / Igarashi, Takahiro; Saikawa, Yoshiro; Kumagai, Koshi; Nakamura, Rieko; Takahashi, Tsunehiro; Takeuchi, Yuya; Kitagawa, Yuukou.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 36, No. 8, 08.2009, p. 1363-1366.

Research output: Contribution to journalArticle

Igarashi, Takahiro ; Saikawa, Yoshiro ; Kumagai, Koshi ; Nakamura, Rieko ; Takahashi, Tsunehiro ; Takeuchi, Yuya ; Kitagawa, Yuukou. / Report of a case successfully treated with chemo-radiation against local recurrence after gastric cancer surgery. In: Japanese Journal of Cancer and Chemotherapy. 2009 ; Vol. 36, No. 8. pp. 1363-1366.
@article{50517700287241caaead5f2a04b17ab4,
title = "Report of a case successfully treated with chemo-radiation against local recurrence after gastric cancer surgery",
abstract = "A 68-year-old male was diagnosed as type 2 gastric cancer in the upper part of the stomach, then diagnosed as cT2 (MP) N0M0H0P0, cStage I B. Total gastrectomy and splenectomy with D2 lymph node dissection were performed. Final diagnosis including pathology was pT1 (SM) N1M0H0P0, pStage IB, and with his informed consent, an anti-cancer drug, UFT, was given as postoperative adjuvant therapy. Four months after the surgery, a 35-mm sized tumor recurring around the distal region of pancreas was detected by abdominal computed tomography (ACT). Then, combination chemo-radiotherapy using S-1, cisplatin and radiation (50 Gy) was performed. One year after the initial surgery, ACT showed a complete response (CR) of the recurred tumor, while outpatient chemotherapy with S-1+CPT-11 and S-1+paclitaxel was continuously performed, because of elevated CEA. Two years after initial surgery, the CEA value was elevated to 28.4 ng/mL, and so S-1 +docetaxel was applied. The patient is still alive with no sign of lesion recurrence by CT 3 years after initial surgery. Outpatient chemotherapy helped the patient maintain good quality of life. In addition, initial therapy for the recurred tumor including radiation proved to be a powerful way to control local growth of gastric cancer, even if hematogenous/lymphatic spreading of gastric cancer cells might be difficult to suppress with such chemo-radiotherapy.",
keywords = "Chemoradiation therapy, Recurrent gastric cancer, S-1",
author = "Takahiro Igarashi and Yoshiro Saikawa and Koshi Kumagai and Rieko Nakamura and Tsunehiro Takahashi and Yuya Takeuchi and Yuukou Kitagawa",
year = "2009",
month = "8",
language = "English",
volume = "36",
pages = "1363--1366",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "8",

}

TY - JOUR

T1 - Report of a case successfully treated with chemo-radiation against local recurrence after gastric cancer surgery

AU - Igarashi, Takahiro

AU - Saikawa, Yoshiro

AU - Kumagai, Koshi

AU - Nakamura, Rieko

AU - Takahashi, Tsunehiro

AU - Takeuchi, Yuya

AU - Kitagawa, Yuukou

PY - 2009/8

Y1 - 2009/8

N2 - A 68-year-old male was diagnosed as type 2 gastric cancer in the upper part of the stomach, then diagnosed as cT2 (MP) N0M0H0P0, cStage I B. Total gastrectomy and splenectomy with D2 lymph node dissection were performed. Final diagnosis including pathology was pT1 (SM) N1M0H0P0, pStage IB, and with his informed consent, an anti-cancer drug, UFT, was given as postoperative adjuvant therapy. Four months after the surgery, a 35-mm sized tumor recurring around the distal region of pancreas was detected by abdominal computed tomography (ACT). Then, combination chemo-radiotherapy using S-1, cisplatin and radiation (50 Gy) was performed. One year after the initial surgery, ACT showed a complete response (CR) of the recurred tumor, while outpatient chemotherapy with S-1+CPT-11 and S-1+paclitaxel was continuously performed, because of elevated CEA. Two years after initial surgery, the CEA value was elevated to 28.4 ng/mL, and so S-1 +docetaxel was applied. The patient is still alive with no sign of lesion recurrence by CT 3 years after initial surgery. Outpatient chemotherapy helped the patient maintain good quality of life. In addition, initial therapy for the recurred tumor including radiation proved to be a powerful way to control local growth of gastric cancer, even if hematogenous/lymphatic spreading of gastric cancer cells might be difficult to suppress with such chemo-radiotherapy.

AB - A 68-year-old male was diagnosed as type 2 gastric cancer in the upper part of the stomach, then diagnosed as cT2 (MP) N0M0H0P0, cStage I B. Total gastrectomy and splenectomy with D2 lymph node dissection were performed. Final diagnosis including pathology was pT1 (SM) N1M0H0P0, pStage IB, and with his informed consent, an anti-cancer drug, UFT, was given as postoperative adjuvant therapy. Four months after the surgery, a 35-mm sized tumor recurring around the distal region of pancreas was detected by abdominal computed tomography (ACT). Then, combination chemo-radiotherapy using S-1, cisplatin and radiation (50 Gy) was performed. One year after the initial surgery, ACT showed a complete response (CR) of the recurred tumor, while outpatient chemotherapy with S-1+CPT-11 and S-1+paclitaxel was continuously performed, because of elevated CEA. Two years after initial surgery, the CEA value was elevated to 28.4 ng/mL, and so S-1 +docetaxel was applied. The patient is still alive with no sign of lesion recurrence by CT 3 years after initial surgery. Outpatient chemotherapy helped the patient maintain good quality of life. In addition, initial therapy for the recurred tumor including radiation proved to be a powerful way to control local growth of gastric cancer, even if hematogenous/lymphatic spreading of gastric cancer cells might be difficult to suppress with such chemo-radiotherapy.

KW - Chemoradiation therapy

KW - Recurrent gastric cancer

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=79959851526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959851526&partnerID=8YFLogxK

M3 - Article

C2 - 19692780

AN - SCOPUS:79959851526

VL - 36

SP - 1363

EP - 1366

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 8

ER -